Atai Brings R-Ketamine Through Phase 1 Bridging Study, Update And…
Clinical-stage biopharmaceutical company atai Life Sciences ATAI announced the dosing of the first subject in phase 1 of its intravenous to subcutaneous phase 1 subsidiary
Home » RKetamine
Clinical-stage biopharmaceutical company atai Life Sciences ATAI announced the dosing of the first subject in phase 1 of its intravenous to subcutaneous phase 1 subsidiary
Recovery after a serious car accident often takes weeks to months, while severe injuries may require a year or longer. The first 72 hours usually
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind
A groundbreaking new analysis from High Rise Financial highlights a severe and escalating crisis inside U.S. nursing homes, where tens of thousands of elderly residents